Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. (Q53462584)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Günter Niegisch

3

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

author name string

P Albers

1

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

S-I Park

2

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

G Fechner

4

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

U Steiner

5

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

J Lehmann

6

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

D Heimbach

7

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

A Heidenreich

8

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

R Fimmers

9

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

R Siener

10

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

AUO Bladder Cancer Group

11

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

publication date

2 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

22

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

2

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

288-294

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ398

21 January 2018

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ398

21 January 2018

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ398

21 January 2018

Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ398

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ398

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ398

21 January 2018

Power and sample size calculations. A review and computer program

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ398

21 January 2018

Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ398

21 January 2018

Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ398

21 January 2018

Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ398

21 January 2018

Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ398

21 January 2018

A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ398

21 January 2018

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ398

21 January 2018

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ398

21 January 2018

Identifiers

10.1093/ANNONC/MDQ398

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/20682548

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53462584&oldid=1561414074"